Study to Compare the Safety and Pharmacokinetics of CKD-397
NCT02645890
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG:
CKD-397
DRUG:
TD+TM
Sponsor
Chong Kun Dang Pharmaceutical